首页|曲妥珠单抗联合SOX方案治疗进展期胃癌的效果及对患者血清肿瘤标志物水平的影响

曲妥珠单抗联合SOX方案治疗进展期胃癌的效果及对患者血清肿瘤标志物水平的影响

扫码查看
目的 探究曲妥珠单抗联合替吉奥+奥沙利铂(SOX)方案治疗进展期胃癌(AGC)的效果及对患者血清肿瘤标志物水平的影响.方法 选取68例AGC患者作为研究对象,并按随机数字表法分成对照组(34例)和研究组(34例).对照组给予SOX方案治疗,研究组给予曲妥珠单抗联合SOX方案治疗.比较2组疗效、血清肿瘤标志物[糖类抗原724(CA724)、癌胚抗原(CEA)、糖类抗原199(CA199)]水平、免疫功能(IgA、IgG、IgM)水平和药物毒副作用发生率的差异.结果 治疗后,研究组总有效率为67.65%,高于对照组的41.18%(P<0.05).治疗后,2组的血清CA724、CEA、CA199水平均低于同组治疗前,且研究组低于对照组(P<0.05);2组的IgA、IgG、IgM水平低于同组治疗前,但研究组的水平高于对照组(P<0.05).2组药物毒副作用的发生率无明显差异(P>0.05).结论 曲妥珠单抗联合SOX方案对AGC的治疗效果显著,能有效降低患者血清肿瘤标志物水平,减弱化疗对机体的免疫抑制功能,且应用较安全.
Curative Effect of Trastuzumab Combined with SOX Regimen on Patients With Advanced Gastric Cancer and Its Influences on Serum Tumor Markers
Objective To explore the curative effect of trastuzumab combined with oxaliplatin+S-1(SOX)regimen on patients with advanced gastric cancer(AGC)and its influences on levels of serum tumor markers.Methods A total of 68 pa-tients with AGC were enrolled as the research objects.According to random number table method,they were divided into the con-trol group(34 cases)and the study group(34 cases).The control group was treated with SOX regimen,while the study group was additionally treated with trastuzumab.The curative effect,serum tumor markers[carbohydrate antigen 724(CA724),carcino-embryonic antigen(CEA),carbohydrate antigen 199(CA199)],immunoglobulins(IgA,IgG,IgM)and incidence of drugs toxic-ity were compared between the 2 groups.Results After treatment,total response rate of the study group was higher than that of the control group(67.65%vs 41.18%,P<0.05).After treatment,levels of serum CA724,CEA and CA199 in both groups were decreased,which were lower in the study group than the control group(P<0.05).After treatment,levels of IgA,IgG and IgM in both groups were decreased,which were higher in the study group than the control group(P<0.05).There was no significant difference in the incidence of drugs toxicity between the 2 groups(P>0.05).Conclusion Trastuzumab combined with SOX regimen has significant curative effect on AGC patients,which can effectively reduce levels of serum tumor markers and weaken immunosuppressive function,with high application safety.

TrastuzumabSOX regimenAdvanced gastric cancerEffectTumor marker

户军燕、邱作栋、周宁、于婷

展开 >

450000 郑州大学第五附属医院

曲妥珠单抗 SOX方案 进展期胃癌 效果 肿瘤标志物

2024

实用癌症杂志
江西省肿瘤医院 江西省肿瘤研究所

实用癌症杂志

影响因子:1.241
ISSN:1001-5930
年,卷(期):2024.39(1)
  • 14